在HER2-阳性和HER2-阴性乳腺癌中,Bcl-2对亚型特异性预后影响
Taeyeong Kim1, Seung Taek Lim2, Hyang Suk Choi3
1Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea.
Scientific reports
|January 6, 2025
概括
这是一种BCL-2蛋白质.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- Bcl-2蛋白是细胞亡的关键调节者,通常与固体瘤的不良预后有关.
- 它在乳腺癌预后中的作用不一致,需要对亚型进行特定调查.
研究的目的:
- 阐明Bcl-2表达在乳腺癌预后中的亚型特定作用.
- 分析基于HER2和ER状态的Bcl-2表达和生存结果之间的关联.
主要方法:
- 在2004-2018年期间接受治疗的617名女性乳腺癌患者的回顾性分析.
- 根据Bcl-2表达 (>10%对比<10%瘤细胞) 来对患者进行分类.
- 卡普兰-梅尔分析以比较Bcl-2,HER2和ER状态分层的无复发间隔 (RFI) 和整体生存期 (OS).
主要成果:
- 在整个队列中,基于Bcl-2状态,没有观察到总体生存差异.
- 在HER2-过度表达的乳腺癌患者中,高Bcl-2表达与不良预后相关.
- 相反,Bcl-2过度表达表明HER2阴性乳腺癌患者的生存率更好,无论ER状态如何.
结论:
- 乳腺癌中Bcl-2的预后影响取决于HER2表达状态.
- 在不同的乳腺癌亚型中,BCL-2可以作为治疗反应和预后的预测生物标志物.
更多相关视频
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
8.9K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.5K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
